Correlations Between Radiation Dose in Bone Marrow and Hematological Toxicity in Patients With Cervical Cancer: A Comparison of 3DCRT, IMRT, and RapidARC
OBJECTIVETo comparatively evaluate the hematological toxicity (HT) associated with 3 concurrent chemoradiotherapies that are routinely used to treat cervical cancer, including 3-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiation therapy (IMRT), and RapidARC and to establish a...
Gespeichert in:
| Veröffentlicht in: | International journal of gynecological cancer 2016-05, Vol.26 (4), p.770-776 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 776 |
|---|---|
| container_issue | 4 |
| container_start_page | 770 |
| container_title | International journal of gynecological cancer |
| container_volume | 26 |
| creator | Chang, Yu Yang, Zhi-Yong Li, Gui-Ling Li, Qin Yang, Qin Fan, Ji-Quan Zhao, Ying-Chao Song, Ying-Qiu Wu, Gang |
| description | OBJECTIVETo comparatively evaluate the hematological toxicity (HT) associated with 3 concurrent chemoradiotherapies that are routinely used to treat cervical cancer, including 3-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiation therapy (IMRT), and RapidARC and to establish a new normal tissue complication probability model of bone marrow (BM) to predict HT in cervical cancer patients undergoing concurrent chemoradiotherapy.
METHODSPatients with cervical cancer (N = 100) who received concurrent cisplatin and whole-pelvic radiotherapy were enrolled in this study. Dosimetric parameters (including V10, V20, V30, and V40 and mean doses to the pelvic bone) and HT were analyzed.
RESULTSThe V20, V30, and V40 and mean doses to the BM were lower in the IMRT and RapidARC groups than in the 3DCRT group, and the RapidARC group had higher V10 and V40 and mean values than the IMRT group. The V20, V30, and V40 and the mean dose to the pelvic bone were positively correlated with HT. Generalized linear normal tissue complication probability models of white blood cell (WBC) and absolute neutrophil cell (ANC) nadirs and BM V20 were established as followsWBC nadir = 3.382 – 4.056 • V20 + 0.295 • baseline of WBC (adjusted R = 0.246, F = 15.847) and ANC nadir = 2.438 – 2.780 • V20 + 0.233 • baseline of ANC (adjusted R = 0.236, F = 16.282).
CONCLUSIONSThis study suggests that IMRT results in milder hematological toxicity than either 3DCRT or RapidARC. Dosimetric parameters were associated with the incidence of HT in cervical cancer patients who received concurrent chemoradiotherapies. |
| doi_str_mv | 10.1097/IGC.0000000000000660 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_2579089523</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2579089523</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3390-86fc5c567eebe76067526cf8ce6323f91f8c655aeede0a54acbec32df43804b23</originalsourceid><addsrcrecordid>eNpdkdtO4zAQhq3VouW0b4CQJW434Nixk3DXmlMlEKgqYu8s15lQQxp3bZfCo_C2uBwktHMxMxp98480P0J7OTnMSV0ejc7lIfkeQpAfaCvnlGd5waqfqSdFlVV1_ncTbYfwkJiakvoX2qSiKgqRsy30Kp330OloXR_wEOIKoMdj3dj3ET5xAbDt8dD1gK-0926Fdd_gC5jr6Dp3b43u8MQ9W2Pjy5q8SYvQx4DvbJxhCf7pHZG6N-CP8QBLN19ob0NSdy1mJ3I8-YNHV-u8Vh7rhW0GY7mLNlrdBfj9WXfQ7dnpRF5kl9fnIzm4zAxjNckq0RpuuCgBplAKIkpOhWkrA4JR1tZ5agXnGqABonmhzRQMo02bXkSKKWU76OBDd-HdvyWEqB7c0vfppKK8rElVc8oStf9JLadzaNTC27n2L-rrkwmoPoCV6yL48NgtV-DVDHQXZyonam2aSqap_01jb2tLhzQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2579089523</pqid></control><display><type>article</type><title>Correlations Between Radiation Dose in Bone Marrow and Hematological Toxicity in Patients With Cervical Cancer: A Comparison of 3DCRT, IMRT, and RapidARC</title><source>Journals@Ovid Ovid Autoload</source><source>MEDLINE</source><creator>Chang, Yu ; Yang, Zhi-Yong ; Li, Gui-Ling ; Li, Qin ; Yang, Qin ; Fan, Ji-Quan ; Zhao, Ying-Chao ; Song, Ying-Qiu ; Wu, Gang</creator><creatorcontrib>Chang, Yu ; Yang, Zhi-Yong ; Li, Gui-Ling ; Li, Qin ; Yang, Qin ; Fan, Ji-Quan ; Zhao, Ying-Chao ; Song, Ying-Qiu ; Wu, Gang</creatorcontrib><description>OBJECTIVETo comparatively evaluate the hematological toxicity (HT) associated with 3 concurrent chemoradiotherapies that are routinely used to treat cervical cancer, including 3-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiation therapy (IMRT), and RapidARC and to establish a new normal tissue complication probability model of bone marrow (BM) to predict HT in cervical cancer patients undergoing concurrent chemoradiotherapy.
METHODSPatients with cervical cancer (N = 100) who received concurrent cisplatin and whole-pelvic radiotherapy were enrolled in this study. Dosimetric parameters (including V10, V20, V30, and V40 and mean doses to the pelvic bone) and HT were analyzed.
RESULTSThe V20, V30, and V40 and mean doses to the BM were lower in the IMRT and RapidARC groups than in the 3DCRT group, and the RapidARC group had higher V10 and V40 and mean values than the IMRT group. The V20, V30, and V40 and the mean dose to the pelvic bone were positively correlated with HT. Generalized linear normal tissue complication probability models of white blood cell (WBC) and absolute neutrophil cell (ANC) nadirs and BM V20 were established as followsWBC nadir = 3.382 – 4.056 • V20 + 0.295 • baseline of WBC (adjusted R = 0.246, F = 15.847) and ANC nadir = 2.438 – 2.780 • V20 + 0.233 • baseline of ANC (adjusted R = 0.236, F = 16.282).
CONCLUSIONSThis study suggests that IMRT results in milder hematological toxicity than either 3DCRT or RapidARC. Dosimetric parameters were associated with the incidence of HT in cervical cancer patients who received concurrent chemoradiotherapies.</description><identifier>ISSN: 1048-891X</identifier><identifier>EISSN: 1525-1438</identifier><identifier>DOI: 10.1097/IGC.0000000000000660</identifier><identifier>PMID: 26844613</identifier><language>eng</language><publisher>England: by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology</publisher><subject>Adult ; Aged ; Antineoplastic Agents - therapeutic use ; Bone marrow ; Bone Marrow - radiation effects ; Cervical cancer ; Chemoradiotherapy - adverse effects ; Cisplatin - therapeutic use ; Dosimetry ; Female ; Follow-Up Studies ; Hematologic Diseases - diagnosis ; Hematologic Diseases - etiology ; Hematology ; Humans ; Middle Aged ; Neoplasm Staging ; Pelvis ; Prognosis ; Radiation therapy ; Radiotherapy Dosage ; Radiotherapy Planning, Computer-Assisted ; Radiotherapy, Conformal - adverse effects ; Radiotherapy, Intensity-Modulated - adverse effects ; Uterine Cervical Neoplasms - pathology ; Uterine Cervical Neoplasms - radiotherapy</subject><ispartof>International journal of gynecological cancer, 2016-05, Vol.26 (4), p.770-776</ispartof><rights>2016 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.</rights><rights>2016 2016 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3390-86fc5c567eebe76067526cf8ce6323f91f8c655aeede0a54acbec32df43804b23</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26844613$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chang, Yu</creatorcontrib><creatorcontrib>Yang, Zhi-Yong</creatorcontrib><creatorcontrib>Li, Gui-Ling</creatorcontrib><creatorcontrib>Li, Qin</creatorcontrib><creatorcontrib>Yang, Qin</creatorcontrib><creatorcontrib>Fan, Ji-Quan</creatorcontrib><creatorcontrib>Zhao, Ying-Chao</creatorcontrib><creatorcontrib>Song, Ying-Qiu</creatorcontrib><creatorcontrib>Wu, Gang</creatorcontrib><title>Correlations Between Radiation Dose in Bone Marrow and Hematological Toxicity in Patients With Cervical Cancer: A Comparison of 3DCRT, IMRT, and RapidARC</title><title>International journal of gynecological cancer</title><addtitle>Int J Gynecol Cancer</addtitle><description>OBJECTIVETo comparatively evaluate the hematological toxicity (HT) associated with 3 concurrent chemoradiotherapies that are routinely used to treat cervical cancer, including 3-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiation therapy (IMRT), and RapidARC and to establish a new normal tissue complication probability model of bone marrow (BM) to predict HT in cervical cancer patients undergoing concurrent chemoradiotherapy.
METHODSPatients with cervical cancer (N = 100) who received concurrent cisplatin and whole-pelvic radiotherapy were enrolled in this study. Dosimetric parameters (including V10, V20, V30, and V40 and mean doses to the pelvic bone) and HT were analyzed.
RESULTSThe V20, V30, and V40 and mean doses to the BM were lower in the IMRT and RapidARC groups than in the 3DCRT group, and the RapidARC group had higher V10 and V40 and mean values than the IMRT group. The V20, V30, and V40 and the mean dose to the pelvic bone were positively correlated with HT. Generalized linear normal tissue complication probability models of white blood cell (WBC) and absolute neutrophil cell (ANC) nadirs and BM V20 were established as followsWBC nadir = 3.382 – 4.056 • V20 + 0.295 • baseline of WBC (adjusted R = 0.246, F = 15.847) and ANC nadir = 2.438 – 2.780 • V20 + 0.233 • baseline of ANC (adjusted R = 0.236, F = 16.282).
CONCLUSIONSThis study suggests that IMRT results in milder hematological toxicity than either 3DCRT or RapidARC. Dosimetric parameters were associated with the incidence of HT in cervical cancer patients who received concurrent chemoradiotherapies.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Bone marrow</subject><subject>Bone Marrow - radiation effects</subject><subject>Cervical cancer</subject><subject>Chemoradiotherapy - adverse effects</subject><subject>Cisplatin - therapeutic use</subject><subject>Dosimetry</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hematologic Diseases - diagnosis</subject><subject>Hematologic Diseases - etiology</subject><subject>Hematology</subject><subject>Humans</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Pelvis</subject><subject>Prognosis</subject><subject>Radiation therapy</subject><subject>Radiotherapy Dosage</subject><subject>Radiotherapy Planning, Computer-Assisted</subject><subject>Radiotherapy, Conformal - adverse effects</subject><subject>Radiotherapy, Intensity-Modulated - adverse effects</subject><subject>Uterine Cervical Neoplasms - pathology</subject><subject>Uterine Cervical Neoplasms - radiotherapy</subject><issn>1048-891X</issn><issn>1525-1438</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpdkdtO4zAQhq3VouW0b4CQJW434Nixk3DXmlMlEKgqYu8s15lQQxp3bZfCo_C2uBwktHMxMxp98480P0J7OTnMSV0ejc7lIfkeQpAfaCvnlGd5waqfqSdFlVV1_ncTbYfwkJiakvoX2qSiKgqRsy30Kp330OloXR_wEOIKoMdj3dj3ET5xAbDt8dD1gK-0926Fdd_gC5jr6Dp3b43u8MQ9W2Pjy5q8SYvQx4DvbJxhCf7pHZG6N-CP8QBLN19ob0NSdy1mJ3I8-YNHV-u8Vh7rhW0GY7mLNlrdBfj9WXfQ7dnpRF5kl9fnIzm4zAxjNckq0RpuuCgBplAKIkpOhWkrA4JR1tZ5agXnGqABonmhzRQMo02bXkSKKWU76OBDd-HdvyWEqB7c0vfppKK8rElVc8oStf9JLadzaNTC27n2L-rrkwmoPoCV6yL48NgtV-DVDHQXZyonam2aSqap_01jb2tLhzQ</recordid><startdate>201605</startdate><enddate>201605</enddate><creator>Chang, Yu</creator><creator>Yang, Zhi-Yong</creator><creator>Li, Gui-Ling</creator><creator>Li, Qin</creator><creator>Yang, Qin</creator><creator>Fan, Ji-Quan</creator><creator>Zhao, Ying-Chao</creator><creator>Song, Ying-Qiu</creator><creator>Wu, Gang</creator><general>by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201605</creationdate><title>Correlations Between Radiation Dose in Bone Marrow and Hematological Toxicity in Patients With Cervical Cancer: A Comparison of 3DCRT, IMRT, and RapidARC</title><author>Chang, Yu ; Yang, Zhi-Yong ; Li, Gui-Ling ; Li, Qin ; Yang, Qin ; Fan, Ji-Quan ; Zhao, Ying-Chao ; Song, Ying-Qiu ; Wu, Gang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3390-86fc5c567eebe76067526cf8ce6323f91f8c655aeede0a54acbec32df43804b23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Bone marrow</topic><topic>Bone Marrow - radiation effects</topic><topic>Cervical cancer</topic><topic>Chemoradiotherapy - adverse effects</topic><topic>Cisplatin - therapeutic use</topic><topic>Dosimetry</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hematologic Diseases - diagnosis</topic><topic>Hematologic Diseases - etiology</topic><topic>Hematology</topic><topic>Humans</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Pelvis</topic><topic>Prognosis</topic><topic>Radiation therapy</topic><topic>Radiotherapy Dosage</topic><topic>Radiotherapy Planning, Computer-Assisted</topic><topic>Radiotherapy, Conformal - adverse effects</topic><topic>Radiotherapy, Intensity-Modulated - adverse effects</topic><topic>Uterine Cervical Neoplasms - pathology</topic><topic>Uterine Cervical Neoplasms - radiotherapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chang, Yu</creatorcontrib><creatorcontrib>Yang, Zhi-Yong</creatorcontrib><creatorcontrib>Li, Gui-Ling</creatorcontrib><creatorcontrib>Li, Qin</creatorcontrib><creatorcontrib>Yang, Qin</creatorcontrib><creatorcontrib>Fan, Ji-Quan</creatorcontrib><creatorcontrib>Zhao, Ying-Chao</creatorcontrib><creatorcontrib>Song, Ying-Qiu</creatorcontrib><creatorcontrib>Wu, Gang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>International journal of gynecological cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chang, Yu</au><au>Yang, Zhi-Yong</au><au>Li, Gui-Ling</au><au>Li, Qin</au><au>Yang, Qin</au><au>Fan, Ji-Quan</au><au>Zhao, Ying-Chao</au><au>Song, Ying-Qiu</au><au>Wu, Gang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Correlations Between Radiation Dose in Bone Marrow and Hematological Toxicity in Patients With Cervical Cancer: A Comparison of 3DCRT, IMRT, and RapidARC</atitle><jtitle>International journal of gynecological cancer</jtitle><addtitle>Int J Gynecol Cancer</addtitle><date>2016-05</date><risdate>2016</risdate><volume>26</volume><issue>4</issue><spage>770</spage><epage>776</epage><pages>770-776</pages><issn>1048-891X</issn><eissn>1525-1438</eissn><abstract>OBJECTIVETo comparatively evaluate the hematological toxicity (HT) associated with 3 concurrent chemoradiotherapies that are routinely used to treat cervical cancer, including 3-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiation therapy (IMRT), and RapidARC and to establish a new normal tissue complication probability model of bone marrow (BM) to predict HT in cervical cancer patients undergoing concurrent chemoradiotherapy.
METHODSPatients with cervical cancer (N = 100) who received concurrent cisplatin and whole-pelvic radiotherapy were enrolled in this study. Dosimetric parameters (including V10, V20, V30, and V40 and mean doses to the pelvic bone) and HT were analyzed.
RESULTSThe V20, V30, and V40 and mean doses to the BM were lower in the IMRT and RapidARC groups than in the 3DCRT group, and the RapidARC group had higher V10 and V40 and mean values than the IMRT group. The V20, V30, and V40 and the mean dose to the pelvic bone were positively correlated with HT. Generalized linear normal tissue complication probability models of white blood cell (WBC) and absolute neutrophil cell (ANC) nadirs and BM V20 were established as followsWBC nadir = 3.382 – 4.056 • V20 + 0.295 • baseline of WBC (adjusted R = 0.246, F = 15.847) and ANC nadir = 2.438 – 2.780 • V20 + 0.233 • baseline of ANC (adjusted R = 0.236, F = 16.282).
CONCLUSIONSThis study suggests that IMRT results in milder hematological toxicity than either 3DCRT or RapidARC. Dosimetric parameters were associated with the incidence of HT in cervical cancer patients who received concurrent chemoradiotherapies.</abstract><cop>England</cop><pub>by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology</pub><pmid>26844613</pmid><doi>10.1097/IGC.0000000000000660</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1048-891X |
| ispartof | International journal of gynecological cancer, 2016-05, Vol.26 (4), p.770-776 |
| issn | 1048-891X 1525-1438 |
| language | eng |
| recordid | cdi_proquest_journals_2579089523 |
| source | Journals@Ovid Ovid Autoload; MEDLINE |
| subjects | Adult Aged Antineoplastic Agents - therapeutic use Bone marrow Bone Marrow - radiation effects Cervical cancer Chemoradiotherapy - adverse effects Cisplatin - therapeutic use Dosimetry Female Follow-Up Studies Hematologic Diseases - diagnosis Hematologic Diseases - etiology Hematology Humans Middle Aged Neoplasm Staging Pelvis Prognosis Radiation therapy Radiotherapy Dosage Radiotherapy Planning, Computer-Assisted Radiotherapy, Conformal - adverse effects Radiotherapy, Intensity-Modulated - adverse effects Uterine Cervical Neoplasms - pathology Uterine Cervical Neoplasms - radiotherapy |
| title | Correlations Between Radiation Dose in Bone Marrow and Hematological Toxicity in Patients With Cervical Cancer: A Comparison of 3DCRT, IMRT, and RapidARC |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T08%3A35%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Correlations%20Between%20Radiation%20Dose%20in%20Bone%20Marrow%20and%20Hematological%20Toxicity%20in%20Patients%20With%20Cervical%20Cancer:%20A%20Comparison%20of%203DCRT,%20IMRT,%20and%20RapidARC&rft.jtitle=International%20journal%20of%20gynecological%20cancer&rft.au=Chang,%20Yu&rft.date=2016-05&rft.volume=26&rft.issue=4&rft.spage=770&rft.epage=776&rft.pages=770-776&rft.issn=1048-891X&rft.eissn=1525-1438&rft_id=info:doi/10.1097/IGC.0000000000000660&rft_dat=%3Cproquest_pubme%3E2579089523%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2579089523&rft_id=info:pmid/26844613&rfr_iscdi=true |